Symbols / GNLX
GNLX Chart
About
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 124.76M |
| Enterprise Value | 85.66M | Income | -31.87M | Sales | — |
| Book/sh | 0.49 | Cash/sh | 0.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | — | Forward P/E | -2.98 | PEG | — |
| P/S | inf | P/B | 5.65 | P/C | — |
| EV/EBITDA | -2.57 | EV/Sales | — | Quick Ratio | 4.08 |
| Current Ratio | 4.20 | Debt/Eq | 8.73 | LT Debt/Eq | — |
| EPS (ttm) | -0.88 | EPS next Y | -0.94 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-04 19:00 | ROA | -64.27% |
| ROE | -123.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 44.72M |
| Shs Float | 30.64M | Short Float | 7.19% | Short Ratio | 8.65 |
| Short Interest | — | 52W High | 8.54 | 52W Low | 1.99 |
| Beta | 0.18 | Avg Volume | 237.98K | Volume | 197.77K |
| Target Price | $19.33 | Recom | None | Prev Close | $2.70 |
| Price | $2.79 | Change | 3.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.33
Mean price target
2. Current target
$2.79
Latest analyst target
3. DCF / Fair value
$-4.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.79
Low
$10.00
High
$31.00
Mean
$19.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-21 | init | Lake Street | — → Buy | $16 |
| 2025-07-21 | init | LUCID CAPITAL MARKETS | — → Buy | $10 |
| 2025-05-08 | main | Benchmark | Speculative Buy → Speculative Buy | $23 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-11-15 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-29 | init | Guggenheim | — → Buy | $8 |
| 2024-08-27 | init | Roth MKM | — → Buy | $10 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-06-03 | reit | Benchmark | Speculative Buy → Speculative Buy | $25 |
| 2024-05-31 | main | Benchmark | Speculative Buy → Speculative Buy | $25 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-04-03 | reit | Benchmark | Speculative Buy → Speculative Buy | $30 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2023-11-27 | init | HC Wainwright & Co. | — → Buy | $35 |
| 2023-11-24 | main | Benchmark | Speculative Buy → Speculative Buy | $30 |
| 2023-09-12 | init | Maxim Group | — → Buy | $40 |
| 2023-06-09 | main | Benchmark | Speculative Buy → Speculative Buy | $38 |
| 2023-05-18 | init | Brookline Capital | — → Hold | $25 |
| 2023-02-15 | init | Benchmark | — → Speculative Buy | $10 |
- $GNLX stock is down 30% today. Here's what we see in our data. - Quiver Quantitative hu, 06 Nov 2025 08
- Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan Wed, 07 Jan 2026 08
- Genelux president sells $66k in GNLX stock - Investing.com hu, 11 Dec 2025 08
- Lake Street Initiates Coverage of Genelux (GNLX) with Buy Recommendation - Nasdaq ue, 21 Oct 2025 07
- Genelux: An Oncolytic Virus Player About To Cross The Phase 3 Finish Line, But On Shaky Ground - Seeking Alpha hu, 13 Nov 2025 08
- Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - Yahoo Finance Sun, 05 Oct 2025 07
- Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail ue, 03 Feb 2026 08
- Genelux Corporation's (NASDAQ:GNLX) 16% loss last week hit both individual investors who own 58% as well as institutions - simplywall.st hu, 20 Nov 2025 08
- Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates - GlobeNewswire Wed, 05 Nov 2025 08
- New medical chief to guide late-stage trials for cancer immunotherapy - Stock Titan Fri, 02 Jan 2026 08
- Genelux stock falls after announcing proposed public offering - Investing.com Wed, 07 Jan 2026 08
- Genelux Appoints Veteran Oncologist Jason Litten as CMO - The Globe and Mail Sat, 03 Jan 2026 08
- Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st ue, 06 Jan 2026 08
- Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance Fri, 28 Mar 2025 07
- Insider Sale: SVP of $GNLX Sells 3,219 Shares - Quiver Quantitative Fri, 12 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2332 | 8740 | — | Sale at price 3.36 - 5.37 per share. | SMALLING RALPH | Officer | — | 2025-12-05 00:00:00 | D |
| 1 | 10000 | 50008 | — | Sale at price 5.00 per share. | THOMAS JOHN | Director | — | 2025-12-01 00:00:00 | D |
| 2 | 3706 | 14361 | — | Sale at price 3.33 - 5.37 per share. | CAPPELLO JOSEPH | Officer | — | 2025-11-17 00:00:00 | D |
| 3 | 17182 | 66370 | — | Sale at price 3.33 - 5.37 per share. | ZINDRICK THOMAS | Chief Executive Officer | — | 2025-11-17 00:00:00 | D |
| 4 | 4192 | 16032 | — | Sale at price 3.36 - 5.37 per share. | YU YONG | Officer | — | 2025-11-17 00:00:00 | D |
| 5 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | SMALLING RALPH | Officer | — | 2025-08-29 00:00:00 | D |
| 6 | 107500 | — | — | Stock Award(Grant) at price 0.00 per share. | CAPPELLO JOSEPH | Chief Technology Officer | — | 2025-08-27 00:00:00 | D |
| 7 | 22283 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITHER JOHN W | Director | — | 2025-08-27 00:00:00 | D |
| 8 | 22283 | — | — | Stock Award(Grant) at price 0.00 per share. | TYREE JAMES L | Director | — | 2025-08-27 00:00:00 | D |
| 9 | 361200 | — | — | Stock Award(Grant) at price 0.00 per share. | ZINDRICK THOMAS | Officer | — | 2025-08-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 65.94K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -29.34M | -26.05M | -2.04M | -14.12M |
| TotalUnusualItems | 370.00K | -402.00K | 314.00K | 50.00K |
| TotalUnusualItemsExcludingGoodwill | 370.00K | -402.00K | 314.00K | 50.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -29.87M | -28.30M | -5.21M | -16.38M |
| ReconciledDepreciation | 903.00K | 1.02M | 968.00K | 895.00K |
| EBITDA | -28.97M | -26.46M | -1.73M | -14.07M |
| EBIT | -29.87M | -27.48M | -2.70M | -14.96M |
| NetInterestIncome | 1.46M | -3.73M | -1.41M | -1.81M |
| InterestExpense | 0.00 | 822.00K | 1.41M | 1.42M |
| InterestIncome | 1.46M | 244.00K | 0.00 | |
| NormalizedIncome | -30.24M | -27.89M | -5.46M | -16.43M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -29.87M | -28.30M | -5.21M | -16.38M |
| TotalExpenses | 31.70M | 24.34M | 14.08M | 14.61M |
| TotalOperatingIncomeAsReported | -31.70M | -24.16M | -3.01M | -14.61M |
| DilutedAverageShares | 31.45M | 24.43M | 23.65M | 23.65M |
| BasicAverageShares | 31.45M | 24.43M | 23.65M | 23.65M |
| DilutedEPS | -0.95 | -1.16 | -0.22 | -0.69 |
| BasicEPS | -0.95 | -1.16 | -0.22 | -0.69 |
| DilutedNIAvailtoComStockholders | -29.87M | -28.30M | -5.21M | -16.38M |
| NetIncomeCommonStockholders | -29.87M | -28.30M | -5.21M | -16.38M |
| NetIncome | -29.87M | -28.30M | -5.21M | -16.38M |
| NetIncomeIncludingNoncontrollingInterests | -29.87M | -28.30M | -5.21M | -16.38M |
| NetIncomeContinuousOperations | -29.87M | -28.30M | -5.21M | -16.38M |
| TaxProvision | 0.00 | 1.10M | 0.00 | |
| PretaxIncome | -29.87M | -28.30M | -4.11M | -16.38M |
| OtherIncomeExpense | 370.00K | -402.00K | 314.00K | 50.00K |
| SpecialIncomeCharges | 370.00K | -402.00K | 314.00K | 50.00K |
| OtherSpecialCharges | -370.00K | 402.00K | -314.00K | -50.00K |
| NetNonOperatingInterestIncomeExpense | 1.46M | -3.73M | -1.41M | -1.81M |
| TotalOtherFinanceCost | 3.15M | 398.00K | ||
| InterestExpenseNonOperating | 0.00 | 822.00K | 1.41M | 1.42M |
| InterestIncomeNonOperating | 1.46M | 244.00K | 0.00 | |
| OperatingIncome | -31.70M | -24.16M | -3.01M | -14.61M |
| OperatingExpense | 31.70M | 24.34M | 14.08M | 14.61M |
| ResearchAndDevelopment | 19.00M | 12.77M | 9.08M | 6.32M |
| SellingGeneralAndAdministration | 12.71M | 11.57M | 5.00M | 8.29M |
| GeneralAndAdministrativeExpense | 12.71M | 11.57M | 5.00M | 8.29M |
| OtherGandA | 4.01M | 3.72M | 1.10M | 3.44M |
| InsuranceAndClaims | 966.00K | 1.08M | 334.00K | 316.00K |
| SalariesAndWages | 7.73M | 6.77M | 3.57M | 4.54M |
| TotalRevenue | 8.00K | 170.00K | 11.07M | 0.00 |
| OperatingRevenue | 8.00K | 170.00K | 11.07M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 433.33K | 433.33K | ||
| OrdinarySharesNumber | 34.73M | 26.79M | 23.57M | 23.57M |
| ShareIssued | 35.16M | 27.22M | 23.57M | 23.57M |
| NetDebt | 24.53M | 19.68M | ||
| TotalDebt | 1.87M | 2.52M | 26.35M | 25.31M |
| TangibleBookValue | 26.27M | 19.47M | -35.80M | -33.13M |
| InvestedCapital | 26.27M | 19.47M | -10.88M | -8.96M |
| WorkingCapital | 24.64M | 17.65M | -29.73M | -16.66M |
| NetTangibleAssets | 26.27M | 19.47M | -35.78M | -33.11M |
| CapitalLeaseObligations | 1.87M | 2.52M | 1.43M | 1.13M |
| CommonStockEquity | 26.27M | 19.47M | -35.80M | -33.13M |
| PreferredStockEquity | 22.00K | 22.00K | ||
| TotalCapitalization | 26.27M | 19.47M | -27.26M | -15.09M |
| TotalEquityGrossMinorityInterest | 26.27M | 19.47M | -35.78M | -33.11M |
| StockholdersEquity | 26.27M | 19.47M | -35.78M | -33.11M |
| GainsLossesNotAffectingRetainedEarnings | 64.00K | 14.00K | 2.00K | 2.00K |
| OtherEquityAdjustments | 64.00K | 14.00K | 2.00K | 2.00K |
| TreasuryStock | 433.00K | 433.00K | 433.00K | 433.00K |
| RetainedEarnings | -251.39M | -221.52M | -189.78M | -184.58M |
| AdditionalPaidInCapital | 278.00M | 241.39M | 154.40M | 151.87M |
| CapitalStock | 35.00K | 27.00K | 31.00K | 31.00K |
| CommonStock | 35.00K | 27.00K | 9.00K | 9.00K |
| PreferredStock | 0.00 | 0.00 | 22.00K | 22.00K |
| TotalLiabilitiesNetMinorityInterest | 8.44M | 8.42M | 41.31M | 41.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.54M | 1.87M | 9.69M | 18.75M |
| LongTermDebtAndCapitalLeaseObligation | 1.54M | 1.87M | 9.69M | 18.75M |
| LongTermCapitalLeaseObligation | 1.54M | 1.87M | 1.16M | 731.00K |
| LongTermDebt | 8.52M | 18.02M | ||
| CurrentLiabilities | 6.90M | 6.55M | 31.63M | 22.48M |
| OtherCurrentLiabilities | 169.00K | |||
| CurrentDeferredLiabilities | 0.00 | 170.00K | 4.50M | |
| CurrentDeferredRevenue | 0.00 | 170.00K | 4.50M | |
| CurrentDebtAndCapitalLeaseObligation | 329.00K | 653.00K | 16.66M | 6.56M |
| CurrentCapitalLeaseObligation | 329.00K | 653.00K | 266.00K | 402.00K |
| CurrentDebt | 16.40M | 6.16M | ||
| OtherCurrentBorrowings | 15.41M | 6.16M | ||
| CurrentNotesPayable | 0.00 | 992.00K | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.85M | 2.85M | ||
| PayablesAndAccruedExpenses | 6.57M | 5.90M | 14.62M | 8.57M |
| CurrentAccruedExpenses | 1.00M | 2.12M | 7.85M | 4.11M |
| InterestPayable | 0.00 | 5.00M | 4.11M | |
| Payables | 5.57M | 3.78M | 6.78M | 4.46M |
| AccountsPayable | 5.57M | 3.78M | 6.78M | 4.46M |
| TotalAssets | 34.72M | 27.89M | 5.53M | 8.13M |
| TotalNonCurrentAssets | 3.17M | 3.69M | 3.64M | 2.30M |
| OtherNonCurrentAssets | 92.00K | 92.00K | 92.00K | 92.00K |
| NonCurrentDeferredAssets | 0.00 | 1.57M | 0.00 | |
| NetPPE | 3.08M | 3.60M | 1.98M | 2.21M |
| AccumulatedDepreciation | -3.68M | -3.45M | -2.95M | -2.40M |
| GrossPPE | 6.76M | 7.05M | 4.93M | 4.61M |
| Leases | 1.86M | 557.00K | 557.00K | 557.00K |
| ConstructionInProgress | 0.00 | 995.00K | 0.00 | |
| OtherProperties | 4.63M | 5.22M | 4.10M | 3.78M |
| MachineryFurnitureEquipment | 275.00K | 275.00K | 275.00K | 275.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 31.55M | 24.20M | 1.89M | 5.82M |
| OtherCurrentAssets | 653.00K | 1.01M | 1.50M | 1.33M |
| PrepaidAssets | 1.33M | |||
| CashCashEquivalentsAndShortTermInvestments | 30.89M | 23.19M | 397.00K | 4.50M |
| OtherShortTermInvestments | 22.33M | 13.77M | 0.00 | |
| CashAndCashEquivalents | 8.56M | 9.42M | 397.00K | 4.50M |
| CashEquivalents | 7.58M | 7.92M | ||
| CashFinancial | 987.00K | 1.49M | 397.00K | 4.50M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -21.61M | -21.30M | -3.62M | -6.58M |
| RepaymentOfDebt | 0.00 | -685.00K | -130.00K | -1.50M |
| IssuanceOfDebt | 0.00 | 900.00K | 1.10M | 937.00K |
| IssuanceOfCapitalStock | 27.82M | 39.65M | 0.00 | 143.00K |
| CapitalExpenditure | -381.00K | -1.02M | -49.00K | |
| InterestPaidSupplementalData | 0.00 | 72.00K | 264.00K | 912.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 8.56M | 9.42M | 397.00K | 4.50M |
| BeginningCashPosition | 9.42M | 397.00K | 4.50M | 11.35M |
| ChangesInCash | -853.00K | 9.02M | -4.10M | -6.86M |
| FinancingCashFlow | 28.51M | 44.02M | -478.00K | -270.00K |
| CashFlowFromContinuingFinancingActivities | 28.51M | 44.02M | -478.00K | -270.00K |
| NetOtherFinancingCharges | -303.00K | -1.57M | ||
| ProceedsFromStockOptionExercised | 688.00K | 4.46M | 120.00K | 145.00K |
| NetCommonStockIssuance | 27.82M | 39.65M | 0.00 | 143.00K |
| CommonStockIssuance | 27.82M | 39.65M | 0.00 | 143.00K |
| NetIssuancePaymentsOfDebt | 0.00 | 215.00K | 970.00K | -558.00K |
| NetShortTermDebtIssuance | 0.00 | 215.00K | 1.10M | |
| ShortTermDebtPayments | 0.00 | -685.00K | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 900.00K | 1.10M | |
| NetLongTermDebtIssuance | 0.00 | -130.00K | -558.00K | |
| LongTermDebtPayments | 0.00 | -130.00K | -1.50M | |
| LongTermDebtIssuance | 1.10M | 937.00K | ||
| InvestingCashFlow | -8.13M | -14.72M | -49.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -8.13M | -14.72M | -49.00K | 0.00 |
| NetInvestmentPurchaseAndSale | -7.75M | -13.70M | 0.00 | |
| SaleOfInvestment | 21.25M | 0.00 | ||
| PurchaseOfInvestment | -29.00M | -13.70M | 0.00 | |
| NetPPEPurchaseAndSale | -381.00K | -1.02M | -49.00K | 0.00 |
| PurchaseOfPPE | -381.00K | -1.02M | -49.00K | 0.00 |
| OperatingCashFlow | -21.23M | -20.27M | -3.57M | -6.58M |
| CashFlowFromContinuingOperatingActivities | -21.23M | -20.27M | -3.57M | -6.58M |
| ChangeInWorkingCapital | 751.00K | -3.28M | -1.69M | 4.08M |
| ChangeInOtherWorkingCapital | -170.00K | -4.33M | 4.50M | |
| ChangeInOtherCurrentLiabilities | -651.00K | -523.00K | -389.00K | -284.00K |
| ChangeInPayablesAndAccruedExpense | 1.04M | -3.07M | 3.20M | 1.08M |
| ChangeInAccruedExpense | -1.11M | -713.00K | 883.00K | 325.00K |
| ChangeInInterestPayable | 0.00 | 22.00K | 886.00K | 310.00K |
| ChangeInPayable | 2.16M | -2.36M | 2.31M | 754.00K |
| ChangeInAccountPayable | 2.16M | -2.36M | 2.31M | 754.00K |
| ChangeInPrepaidAssets | 359.00K | 483.00K | -168.00K | -1.21M |
| OtherNonCashItems | 1.67M | 1.59M | -56.00K | 196.00K |
| StockBasedCompensation | 6.07M | 5.20M | 2.42M | 4.27M |
| AmortizationOfSecurities | -757.00K | -62.00K | 0.00 | |
| DepreciationAmortizationDepletion | 903.00K | 1.02M | 968.00K | 895.00K |
| DepreciationAndAmortization | 903.00K | 1.02M | 968.00K | 895.00K |
| Depreciation | 903.00K | 1.02M | 968.00K | 895.00K |
| OperatingGainsLosses | 3.55M | 348.00K | ||
| GainLossOnInvestmentSecurities | 3.15M | 398.00K | ||
| NetIncomeFromContinuingOperations | -29.87M | -28.30M | -5.21M | -16.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GNLX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|